Inactive Instrument

IceCure Medical Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Advanced Medical Equipment & Technology

Sales 2024 * 4.26M 1.6B Sales 2025 * 9.53M 3.59B Capitalization 55.79M 21B
Net income 2024 * -13M -4.89B Net income 2025 * -12M -4.52B EV / Sales 2024 * 13.1 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 5.85 x
P/E ratio 2024 *
-4.36 x
P/E ratio 2025 *
-4.88 x
Employees 74
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.7%
More Fundamentals * Assessed data
Dynamic Chart
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense CI
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes CI
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating MT
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study CI
IceCure Medical Ltd. Announces Results from an Independent Study CI
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study CI
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company?s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda?S Prior Denial of Icecure?S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer CI
Sector Update: Health Care Stocks Fall Premarket Tuesday MT
IceCure Medical Regains Nasdaq Compliance MT
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients CI
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense CI
More news
Managers TitleAgeSince
Chief Executive Officer 63 16-08-31
Director of Finance/CFO 54 17-04-30
Chief Tech/Sci/R&D Officer 47 18-03-24
Members of the board TitleAgeSince
Director/Board Member 72 12-08-14
Director/Board Member 68 13-07-31
Director/Board Member 61 22-12-03
More insiders
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
More about the company